What is Intelligencia AI?
Intelligencia AI operates at the intersection of artificial intelligence and clinical development, providing a sophisticated platform designed to minimize the financial and operational risks of drug discovery. The company serves as a strategic bridge for R&D and Business Development leaders, offering predictive analytics that transform how clinical programs are evaluated and managed. By synthesizing vast datasets, Intelligencia AI enables stakeholders to assess the viability of internal pipelines and external acquisition opportunities with unprecedented precision. Its market position is defined by its ability to replace intuition-based decision-making with rigorous, evidence-backed insights, effectively reducing the high failure rates typically associated with pharmaceutical innovation.
How much funding has Intelligencia AI raised?
Intelligencia AI has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2021): $12M with participation from Synetro Group, Big Pi Ventures, and Mtip
Key Investors in Intelligencia AI
Synetro Group
Synetro Group is a Chicago-based private investment and strategic advisory firm that specializes in technology and business services, focusing on B2B SaaS and health tech sectors.
Big Pi Ventures
Big Pi Ventures is a multi-stage technology investment platform with a global focus, dedicated to supporting high-growth tech businesses across early and late-stage cycles.
Mtip
MTIP is a Swiss growth and buyout firm that specializes in acquiring and investing in profitable, high-growth healthcare software companies with recurring revenue models.
What's next for Intelligencia AI?
With this major enterprise-level funding, Intelligencia AI is poised to expand its footprint within the global biotech ecosystem. The strategic roadmap likely includes the enhancement of its predictive modeling capabilities and the expansion of its commercial reach to support larger, multi-national pharmaceutical organizations. As the industry continues to prioritize efficiency in drug development, Intelligencia AI is well-positioned to capture significant market share by providing the analytical infrastructure necessary for modern R&D success. Future growth will likely focus on deepening integration with existing enterprise software suites and scaling its advisory services to meet the increasing demand for data-driven clinical oversight.
See full Intelligencia AI company page
